Grants and Contributions:

Back to search

Title:

StressMarq biosciences - alpha synuclein oligomer antibody validation

Agreement Number:

EGP

Agreement Value:

$25,000.00

Agreement Date:

Jun 14, 2017 -

Organization:

Natural Sciences and Engineering Research Council of Canada

Location:

British Columbia, CA

Reference Number:

GC-2017-Q1-00510

Agreement Type:

Grant

Report Type:

Grants and Contributions

Additional Information:

Grant or Award spanning more than one fiscal year. (2017-2018 to 2018-2019)

Recipient's Legal Name:

Christie, Brian (University of Victoria)

Program:

Engage Grants for Universities

Program Purpose:

This project will allow StressMarq, a company that specializes in making antibodies, and Dr. Christie'sx000D
laboratory at the University of Victoria to investigate a novel alpha synuclein aggregate. This aggregate hasx000D
prion-like properties, and is able - when active - to catalyze the formation of Lewy Bodies in vivo fromx000D
endogenous alpha synuclein monomers found in the host environment. Lewy Bodies are a hallmark of Lewyx000D
Body dementia, often described as being a subset of Parkinson's disease (approximately 25% of Parkinson'sx000D
patients have this pathology). The project will involve "mapping" the expression of the pathology and activityx000D
of the antibody using immunohistochemistry on rat or mouse brain slices harvested from animals with varyingx000D
controlled neurological backgrounds, something routinely done in the Christie laboratory. The ability to workx000D
with cell culture would show if the antibody can neutralize the Lewy Body pathology when induced in thesex000D
cells, and if successful, the same could be carried out in rats.